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amyotrophic lateral sclerosis demonstrated by
paraffin-embedded tissue (PET) blot
Petra Steinacker1*, Christian Berner1, Dietmar R Thal2, Johannes Attems3, Albert C Ludolph1 and Markus Otto1*Abstract
Objectives: The paraffin-embedded tissue (PET) blot technique followed by limited protease digestion has been
established to detect protein aggregates in prion diseases, alpha-synucleopathies, and tauopathies. We analyzed
whether the scope of the method can be extended to analyze aggregates in mouse and human tissue with
amyotrophic lateral sclerosis (ALS) associated with superoxide dismutase 1 (SOD1) mutation.
Methods: Formalin-fixed and paraffin-embedded brain and spinal cord tissue from SOD1G93A mice was first
analyzed for the expression of SOD1, aggregated SOD1, ubiquitin, and p62 by convential immunohistochemistry
and then used to establish the PET blot technique, limited protease digest, and immunodetection of SOD1
aggregates. The method was then transferred to spinal cord from an ALS patient with SOD1E100G mutation.
Results: Mouse and human paraffin-embedded brain and spinal cord tissue can be blotted to membranes and
stained with anti-SOD1 antibodies. The SOD1 labelling is abolished after limited proteolytic digest in controls,
whereas under identical conditions SOD1 aggregates are detected the SOD1G93A mouse model of ALS and in
human familial ALS. The most prominent areas where aggregates could be detected are the brainstem and the
anterior horn of the spinal cord.
Discussion: Applicability of the PET blot technique to demonstrate SOD1 aggregates in ALS tissue associated with
mutations in the SOD1 gene offers a new approach to examine potential spreading of aggregates in the course of
ALS.
Keywords: Amyotrophic lateral sclerosis, Superoxide dismutase 1, Protein aggregates, p62, UbiquitinIntroduction
Neurodegenerative diseases are characterized by the ac-
cumulation of proteins with aberrant conformation in
the affected tissues. Disturbances of mechanisms that
normally ensure clearance of misfolded proteins have
been identified to underlie or contribute the deposition.
Included here are e.g. dysfunction of the chaperone ma-
chinery, failure of the proteasomal system [1,2], and im-
pairment of autophagic mechanisms [3]. Recently, it was
recognized that template assisted misfolding or seeded
polymerization contributes to the burden of protein ag-
gregates in a number of proteinopathies, comparable to* Correspondence: petra.steinacker@uni-ulm.de; markus.otto@uni-ulm.de
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article, unless otherwise stated.the propagation of conformationally changed prion pro-
tein in prion diseases [4,5].
Amyotrophic lateral sclerosis (ALS) is a phenotypically
heterogeneous disease characterized by degeneration of
upper and lower motoneurons. 90% of ALS cases are
sporadic and 10% are caused by mutations in different
genes. Around 20% of the familial cases are associated
with mutations in the Cu/Zn superoxide dismutase 1
(SOD1) [6]. Mutated SOD1 forms aggregates of fibrillar
structure in the affected tissues [7,8] and recent data
suggest that there is also a propensity for aggregation of
posttranslationally modified wild type SOD1 in a subset
of sporadic ALS cases [9]. Misfolding and aggregation of
SOD1 in the spinal cord and the motor cortex is also
observed in mice transgenic for disease associated mu-
tated human SOD1 representing the most establishedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ubiquitin and p62 [11,12].
The misfolding state depends on the mutation and on
the method of detection [13]. Some antibodies were gen-
erated and are in part commercially available which are
reported to solely recognize misfolded SOD1. A way to
detect misfolded proteins independently on antibodies
recognizing the misfolded form is to subject tissue or
homogenates from animals or humans with a proteino-
pathy to a limited protease digest, leading to destruction
of the physiologically folded protein but leaving off the
conformationally changed form(s), which afterwards can
be immunodetected by non-conformation-specific anti-
bodies. A method that was initially established for the
detection of misfolded prion protein in fixed tissue from
patients or animals with prion disease [14,15] is the
paraffin-embedded tissue (PET) blot technique. This
technique combines the advantages from highly sensitive
immunohistochemistry, reveals anatomical resolution
and can be performed with paraffin-embedded tissue.
Here we report on the applicability of the PET blot
technique for the detection of misfolded SOD1 in
paraffin-embedded tissue from ALS mice and from hu-
man fALS post-mortem tissue.
Material and methods
Mice breeding
The principles of laboratory animal care were followed
and use of the mice was performed in accordance with
the national guidelines and was approved by local au-
thorities. Male mice transgenic for human SOD1G93A
(huSOD1G93A, B6.Cg-Tg[SOD1-G93A]1Gur/J; stock
number 004435) were acquired from the Jackson labora-
tory (Ben Harbor, Maine). These transgenic mice are
characterized by survival times of 128.9+/−9.1 days. By
breeding with female C57Bl/6J from an in-house breed
wild type mice and SOD1G93A littermates of either sex
were generated for the experiments. At terminal disease
state the mice used for establishment of the PET-blot
were between 132 and 159 days old.
Tissue preparation
Mice at terminal disease stage were anesthetized and
transcardially perfused with PBS for cryoconservation of
the tissue or by PBS followed by paraformaldehyde in
case of subsequent paraffin embedding as published
elsewhere [16]. Prepared were the spinal cords as well
as the whole brains separated sagittally into the two
hemispheres.
The study of human control tissue was performed in
compliance with university ethics committee guidelines
and the laws governing human tissue usage in the Ger-
man federal state of Baden-Württemberg. Consent for
autopsy was obtained for all patients and controls orfrom their next of kin. Brain tissue of the ALS case was
collected by the Newcastle Brain Tissue Resource
(NBTR) at Newcastle University, UK, after relevant in-
formed consent from the donor and in accordance with
Newcastle University ethics board and ethical approval
awarded by The Joint Ethics Committee of Newcastle
and North Tyneside Health Authority (reference: 08/
H0906/136).
Two control cases were studied: 1. male, 38 years of
age, head trauma, (neuropathological staging: Braak
NFT 0 [17], Abeta phase 0 [18], Braak PD stage 0 [19]);
2. female 72 years of age, ruptured aortic aneurysm
(neuropathological staging: Braak NFT I, Abeta phase
0, Braak PD stage 0.
The ALS case was a female age 48 at death who had
the diagnosis 12 years before death. The mother, two un-
cles and a sister were also affected by ALS. Testing dur-
ing lifetime revealed the E100G mutation in the SOD1
gene. Initial symptoms were cramp and muscle twitching
in legs, progressing to fasciculation in upper limbs and
trunk and lower limb weakness. Marked bulbar symp-
toms developed. There was no apparent cognitive im-
pairment. The cause of death was cardiac arrest and
asphyxia secondary to ALS (neuropathological staging:
Braak stage 0, CERAD score [20] none, no Lewy Body
pathology, no cerebral infarcts).
The spinal cords were removed in toto and fixed in a
4% aqueous solution of formaldehyde for 10–20 days
prior to dissection. The dura mater of each spinal cord
was then opened with a dissecting scissors and anchored
bilaterally with pins to a cork board. After macroscopic
inspection, tissue blocks from the cervical, thoracic,
lumbar, and sacral spinal cord with the dorsal and ven-
tral roots were made, embedded in paraffin, and sec-
tioned at 7 μm in the transversal plane.
Immunohistochemistry
Paraffin-embedded tissue sections (5 μm) were dried
over night at 37°C and immersed in two changes of
5 min xylene and acetone. Deparaffinized sections were
rinsed with water, exposed to microwave and afterwards
endogenous peroxidase was blocked with 3% hydrogen
peroxide in methanol. After 2 washes with PBS for
5 min the sections were perfused with 0.2% Triton in
PBS and then blocked with 10% fetal bovine serum PBS.
Subsequently, the respective primary antibody was di-
luted in blocking solution (polyclonal anti-human SOD1
(abcam ab52950) and anti human/mouse SOD1 anti-
bodies (ab16831), 1:500; anti-ubiquitin, Biorad 9400–
1004, 1:250, monoclonal anti-p62 (SQSTM1), abcam
ab91526, 1:500) and applied over night at 4°C. After 3
washes in PBS for 5 min the sections were either incu-
bated for 1 h at RT with goat-anti-rabbit peroxidase-
coupled secondary antibody (Biorad), washed again 3
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10 min, or incubated with biotin-coupled secondary
anti-mouse antibody (Biorad), washed again and devel-
oped with ABC-kit (Pierce). Counterstaining with 100%
hemalaun was followed by dehydration and mounting of
the slices with entellan.
Paraffin-embedded tissue blot
Pieces of PVDF membrane (20 mm x 50 mm Fluoro-
bind, Serva, Heidelberg, Germany) were prewetted in
methanol for 10 sec followed by water. Sagittal mouse
brain sections of 5 μm or transverse mouse/human spinal
cord sections were cut and put into a water bath at 40°C,
transferred to the prewetted membrane and dehydrated at
55°C for 2 h. Deparaffination/rehydration was carried out
by two changes of 5 in: Xylene, 100% - 96% - 70% ethanol,
TBS (50 mM Tris–HCl pH 7.6, 150 mM NaCl) including
drying of the membrane between xylene and 100% ethanol
and between 70% ethanol and TBS which avoids detach-
ing of the membrane from the glas.
For the establishment of partial proteinase K (PK) di-
gest a series of experiments was carried out applying 5-
250 μg/ml PK for 4-21 h. 5 μg/ml PK and a digestion
time of 15 h was worked out to be best: PK below 5 μg/
ml or digestion times below 15 h yielded results compar-
able to PK-untreated PET-blots and increases in concen-
tration or digestion times above 5 μg/ml 15 h yielded
blank PET-blots. All PK digested PET blots shown were
treated with 5 μg/ml PK added to digest buffer (10 mM
Tris–HCl pH 7.8, 100 mM NaCl, 0.1% Brij) and incu-
bated with the membrane in an oven at 55°C for
15 hours. After the digest the PET-Blots were washed
3 × 5 min in TBS with 0.5% Tween 20 (TBS-T).
The endogenous peroxidase was blocked at RT by in-
cubation with 3% hydrogen peroxide for 5 min. Then
the sections were washed three times with TBS-T for
5 min. Epitope retrieval was achieved by incubation of
the membrane with 4 M guanidiumthiocyanat in 10 mM
Tris–HCl, ph 7.8, for 15 min. After 3 washes (TBS-T
5 min) the blots were blocked (Tropix I-Block, Applied
biosystems, Bedford, U.S.A) for 1 h at RT. Primary anti-
bodies specific for human SOD1 or for mouse&human
SOD1 (both from Abcam,see above)), for 14-3-3 pro-
teins (Santa Cruz sc-629), were diluted 1:1000 in I-
Block, respectively, and incubated with the blots on a
rocker over night at 4°C. Biotinylated secondary anti-
body (Dako, Glostrup, Denmark) diluted 1:500 in I-
Block was added after 3x 10 min washes with TBS-T for
1 h at RT. Excess antibody was washed out 5 times with
TBS-T for 10 min. Subsequently the membranes were
incubated avidin-biotinylated-complex (ABC) solution
for 1.5 hours. After 5 x 10 min wash in TBS-T the blots
were developed by adding 3,3' diaminobenzidine (fast
DAB, Sigma, Steinheim, Germany) for 10 min. Themembranes were mounted on glass slides with a 3:2 ra-
tio of DMSO:96% ethanol.
Pictures were taken with a Zeiss Mirax digital scan-
ning microscope, a Zeiss Axiovert 200 or Axioskop 2plus
microscope, post processing was carried out using adobe
photoshop.
Results
In brain sections from end-stage SOD1G93A mice immu-
nohistochemically (IHC) stained for human SOD1 a
widespread expression of the transgene is visible with
most intense staining in the brain stem, particularly in
motor-associated regions of the pons and the medulla as
well as in midbrain regions, e.g. substantia nigra pars
compacta and the reticular nucleus (Figure 1a). A pro-
nounced staining of the cerebellar molecular layer and a
moderate staining of cerebellar nuclei can be seen. At
higher magnification, the strong staining of the cyto-
plasm of neurons in the medulla oblongata (Figure 1d)
and in the midbrain area becomes visible.
In PET-blots applying anti-human SOD1 antibody
(Figure 1b) a less intense overall staining is observed
which appears to be more uniformly distributed over the
whole tissue compared to the IHC. Taking a closer look
distinct staining becomes visible frequently localized to
the edges of pathologic vacuoles as well as to the cyto-
plasm of neurons in both the medulla oblongata
(Figure 1e) and the midbrain (not shown). When PET
blots are digested with proteinase K at a concentration
of 5 μg/ml for 15 h the edges of the blotted tissues are
barely seen and immunopositive structures are left al-
most entirely in the brain stem (Figure 1c). The struc-
tures that are strongly labelled have a size of few to
around 30 μm and round or (tangled) skein-like shape
(Figure 1f,g). Cellular structures are mostly deleted.
In contrast, staining for endogenous murine SOD1 in
PET-blots of wild type (WT) mice brain sections which
appears relatively uniformly distributed over the blot
with predominantly cytoplasmic staining as shown for
the medulla region (Figure 1h) does not resist proteolytic
digestion with 5 μg/ml protease K for 15 h (Figure 1i).
PET-blots from WT mice brains were also probed with
anti-human SOD1 anibodies yielding no staining (data
not shown) verifying the specificity of antibody binding
in analyses of transgenic tissue.
Brain areas that are strongly positive for transgenic
SOD1 are frequently also positive in PK digested PET-
blots. To exclude that the SOD1 labelling that can be
detected after limited PK digestion is only leftover be-
cause of initially high expression levels, we did experi-
ments applying the PET-blot technique to another
highly expressed protein in the brain, the 14-3-3 protein.
Without proteolysis an intense cytoplasmic staining can
be seen (Figure 1j). By treatment of the PET-blot with
Figure 1 Sagittal brain slices from a SOD1G93A transgenic mouse at terminal disease stage and from control wild type mice.
(a) Immunohistochemistry applying anti-human SOD1 antibody (counterstaining: HE). Most prominent expression can be observed in
motor-associated regions of the pons and the medulla as well as in midbrain regions, e.g. substantia nigra pars compacta and the reticular nucleus. A
pronounced staining of the cerebellar molecular layer and a moderate staining of cerebellar nuclei can be seen. The Ammon’s horn CA1 region as well
as the subiculum is temperately stained. In a detailed view of the medulla oblongata after conventional IHC of human SOD1 in the transgenic mouse
brain tissue intense neuronal cytoplasmic staining as well as staining of the neuropil is visible (d). The edges of pathologic vacuoles are also frequently
stained. In (b) a PET-blot of a sagittal brain slice from a SOD1G93A mouse after staining of human SOD1 is shown. A relatively homogeneous overall
staining can be seen with areas of intense staining mainly in the brain stem. The staining is weaker compared to conventional IHC however the
cytoplasmic as well as vacuole staining is preserved as it is shown at higher magnification of the medulla oblongata (e). When subjecting a PET-blot of
a SOD1G93A mouse to limited protease digestion the residual tissue can be recognized and staining is left in the brain stem (c), appearing as large
SOD1-positive clumps that often have skein-like structure, which is shown for the midbrain (f) and medulla oblongata (g). Controls are shown in (h-k):
PET-blot of a sagittal WT mouse brain section and immunodetection with an antibody against mouse SOD1 without PK treatment (h) and after PK (i)
shows that the endogenous SOD1 is not resistant to PK digestion. PET-blot of a WT mouse brain slice and immunodetection of 14-3-3 proteins without
(j) and after PK digest (k) shows that even the highly expressed 14-3-3 is quantitatively degraded. Bars represent 200 μm (k), 100 μm (d, e, h, i, j), and
50 μm (f, g).
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well as in other brain regions and only faint transparent
tissue derived structures are visible (Figure 1k).
The PET-blot technique can also be applied to transversal
mouse spinal cord sections (HE-stained section in
Figure 2a). High expression of the transgenic human SOD1
is detected by anti-human SOD1 antibodies in the cells in
the grey matter (Figure 2b) and an intense staining of struc-
tures in the grey matter is even obtained after limited pro-
teolytic digest (Figure 2c). This is in contrast to mouse WT
tissue: the staining of PET- blots obtained after probinganti-mouse SOD1 antibodies (Figure 2d) is abolished by PK
treatment (Figure 2e). The labelled structures in the
SOD1G93A spinal cord appear skein-like or tangled
(Figure 2g) as in the brain stem and can hardly be seen in
conventional SOD1 immunohistochemistry (data not
shown) or in PK-untreated SOD1 PET-blots (Figure 2f).
Also in ubiquitin IHC (Figure 2h,i) large labelled structures
are observed but less frequently and they are more difficult
to recognize than in the protease treated SOD1 PET-blot.
We went then to the examination if also human post-
mortem ALS tissue is suitable for the PET-blot analysis
Figure 2 Transversal spinal cord sections (7 μm) from SOD1G93A transgenic mice at terminal disease state and from control mice.
(a) HE-stained section of a SOD1G93A mouse spinal cord. (b) Immunostaining of human SOD1 with PET-blot technique without proteolysis reveals
strong staining of the grey matter of a SOD1G93A spinal cord. If the PET-blot is treated with PK labelling of grey matter area is left (c). In the
PET-blot of control tissue from a wild type mouse also strong labelling applying an antibody recognizing endogenous SOD1 observed (d) which
is completely abolished by limited proteolysis (e). Higher magnification of the PET blots in b and c revealed the pronounced cellular staining in
the ventral horn area of the untreated spinal cord PET-blot (f). In the PK treated PET-blot large numbers of aggregates of different size and shape
are detected (g). Staining with an antibody against ubiquitin is shown in an overview (h) and at higher magnification (i) for comparison. Bars
represent 20 μm (i), 50 μm (g), 100 μm (f), and 200 μm (d, e, h).
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from an ALS patient with the SOD1E100G mutation we
found by SOD1 IHC (overview in Figure 3a) expression
in both neurons and glial cells in the grey matter
(Figure 3d) and glial cells in the white matter (Figure 3e).
In the spinal cord section of a control patient SOD1 is
found in neurons of the grey matter (Figure 3f ) but glial
cells are largely negative. Aggregates in ALS tissue can-
not be obviously seen, when SOD1 is stained. We per-
formed IHC for ubiquitin and for p62. While the
ubiquitin IHC was indistinguishable comparing ALS
with control tissue (Figure 3k,l), neuropathological dif-
ferences can be seen in the ALS tissue stained for p62,
namely occasionally occurring aggregate-like structures
(Figure 3i,j).
When human ALS spinal cord tissue is subjected to
PET-blot SOD1 staining in the white and grey matter is
preserved (Figure 3b,g), however aggregates become
clearly visible when the blotted tissue is PK-treated be-
fore immunodetection (Figure 3c,h).Discussion
In recent years evidence accumulated that in neurode-
generative diseases, including ALS, disease progression
is caused or paralleled by spreading of the disease spe-
cific respective pathological protein. Comparable to
prion diseases, in which the pathological prion protein
propagates by a seeding/nucleation polymerization
process and is transferred from cell to cell, stereotypic
spread has been observed in e.g. synucleopathies and
Alzheimer’s disease [21-24]. For in vitro and in vivo
studies and especially for the examination of the neuro-
pathologically characteristic misfolded, oligomerized and
aggregated proteins discrimination between normal and
aberrant forms is essential.
The PET-blot approach differentiates between normal
and aggregated proteins. It takes advantage of a limited
protease resistance of conformationally changed proteins
compared to the normal forms in tissue sections blotted
onto PVDF or nitrocellulose membranes prior to immu-
nodetection. This was first established for prion diseases
Figure 3 Transverse spinal cord sections from an ALS Patient with SOD1E100G mutation and sections from a control patient. (a) shows a
SOD1 IHC, (b) a SOD1 PET-blot and (c) a protease treated SOD1-PET blot. In the IHC shown in more detail in d-e staining of neurons and glial
cells is visible in the gray matter (arrows and arrow heads in d, respectively). (e) shows that glial cells in the white matter are also stained. (f) In
the control spinal cord section SOD1 is only detected in neurons of the gray matter. In PET-blots SOD1 is labelled in the grey matter as well as in
glial cells in the white matter (g). However, in PK treated PET-blots aggregates are strongly labelled in the grey matter area (h). Aggregates can
only occasionally be seen in p62 IHC (i: ALS, j: control) and are undetectable in ubiquitin IHC (k: control, l: ALS). Bars represent 50 μm (a-f, h-l)
and 100 μm (g).
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ture with high beta sheet content of the pathological prion
protein [15]. The PET-blot technique, which combines
high sensitivity of detection with acceptable histological
resolution, has been shown to be applicable to study ag-
gregate distribution and follow the spreading also in synu-
cleopathies and Alzheimer’s disease [25,26]. This data
tempted us to test if SOD1 aggregates can also be detected
in PET-blots of brain sections from genetic ALS brains.
Especially for the study of post-mortem paraffin-
embedded human ALS brains and spinal cords collected
in biobanks as well as for the longitudinal study of ALS
mouse tissue the development of approaches to track
aggregates during disease progression is important.
Here we show that brain and spinal cord tissue from
SOD1G93A mice and from a patient with SOD1 mutationcan be subjected to the PET-blot method and that aggre-
gates resist a limited protease digest while endogenous/
normal forms of SOD1 are degraded and not longer de-
tected by conventional SOD1 antibody. Compared to
IHC staining of ubiquitin and p62, both of which are
published to bind SOD1 aggregates and are used to
study diseased tissue [27-29], aggregates can easier be
seen and a reliable quantification seems possible.
Recently, antibodies specifically recognizing misfolded
SOD1 have been developed and successfully used for
examination of human and mouse ALS tissue. Some of
these antibodies also react with conformationally chan-
ged post-translationally modified wild-type SOD1 forms
present also in the majority of sALS cases revealing in-
clusions that weren’t seen formally presumably because
of masking by the abundant properly folded SOD1
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differentiate between different misfolded SOD1 forms
with the PET-blot approach, e.g. by applying a range of
proteinase concentrations, however masking of aggre-
gates by reactivity of the antibody to alternative SOD1
forms is not to be expected. Future experiments have
to be conducted to analyse SOD1 aggregates by IHC
with conformation dependent antibodies in order to
compare the results with those that came up from
PET-blots. Beyond that the analysis of PET-blots with
conformation dependent antibodies will probably
extent the detection potential and knowledge about
the behaviour of muSOD1 aggregates during progres-
sion of disease and even of misfolded WT SOD1 in
sporadic ALS.
Different mutations in the SOD1 gene can be associ-
ated with different properties of the protein with regard
to hydrophobicity, di- and oligomerization, aggregation
propensity, and toxicity [33-35]. Localization and track-
ing of mutated SOD1 offers the opportunity to examine
several aspects of ALS, as selective vulnerability of spe-
cific cells, cell to cell transmission, or co-occurrence of
inclusions and neurodegeneration. Exemplarily for hu-
man fALS, we analyzed fixed spinal cord tissue from a
patient with the E100G mutation in the SOD1 gene. For
this mutation posterior column involvement has been
reported and ubiquitinated neuronal inclusions have
been infrequently detected [36]. In the spinal cord sub-
jected to PET-blot aggregates are easily investigatable
and can be localized to areas of the grey matter.
In conclusion, we established a technique for the ana-
lysis of misfolded SOD1 in familial ALS useful in aggre-
gate detection, localization and tracking that is
applicable to biobanked material. Subgroups of ALS
might be identified with different propagation of confor-
mationally changed SOD1.
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